These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1335668)

  • 21. An economic evaluation of hepatitis A vaccination in Dutch military personnel.
    Buma AH; Beutels P; van Damme P; Tormans G; van Doorslaer E; Leentvaar-Kuijpers A
    Mil Med; 1998 Aug; 163(8):564-7. PubMed ID: 9715622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vaccination against hepatitis A].
    Giusti G; Russo M
    Recenti Prog Med; 1992 Jun; 83(6):313-20. PubMed ID: 1323136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).
    Postma MJ; Bos JM; Beutels P; Schilthuis H; van den Hoek JA
    Vaccine; 2004 May; 22(15-16):1862-7. PubMed ID: 15121296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination strategies against hepatitis A in travelers older than 40 years: an economic evaluation.
    Costas L; Vilella A; Trilla A; Serrano B; Vera I; Roldán M; Sancho MP; Bayas JM; Gascón J; Costa J
    J Travel Med; 2009; 16(5):344-8. PubMed ID: 19796106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of viral hepatitis A: past, present and future.
    Deinhardt F
    Vaccine; 1992; 10 Suppl 1():S10-4. PubMed ID: 1335635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination.
    Fujiyama S; Odoh K; Kuramoto I; Mizuno K; Tsurusaki R; Sato T
    J Hepatol; 1994 Oct; 21(4):641-5. PubMed ID: 7814811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C.
    Myers RP; Gregor JC; Marotta PJ
    Hepatology; 2000 Apr; 31(4):834-9. PubMed ID: 10733536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
    Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of hepatitis A virus immunisation in Spain.
    Arnal JM; Frisas O; Garuz R; Antoñanzas F
    Pharmacoeconomics; 1997 Sep; 12(3):361-73. PubMed ID: 10170461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in hepatitis A prevention in travellers.
    Steffen R; Gyurech D
    J Med Virol; 1994 Dec; 44(4):460-2. PubMed ID: 7897382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers.
    Behrens RH; Roberts JA
    BMJ; 1994 Oct; 309(6959):918-22. PubMed ID: 7726905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children.
    Hankin-Wei A; Rein DB; Hernandez-Romieu A; Kennedy MJ; Bulkow L; Rosenberg E; Trigg M; Nelson NP
    Vaccine; 2016 Jul; 34(35):4243-4249. PubMed ID: 27317459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and prevention of hepatitis A in travelers.
    Steffen R; Kane MA; Shapiro CN; Billo N; Schoellhorn KJ; van Damme P
    JAMA; 1994 Sep; 272(11):885-9. PubMed ID: 8078167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing hepatitis A infections in travelers to endemic areas.
    Koff RS
    Am J Trop Med Hyg; 1995 Dec; 53(6):586-90. PubMed ID: 8561258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of hepatitis A prevention in France.
    Severo CA; Fagnani F; Lafuma A
    Pharmacoeconomics; 1995 Jul; 8(1):46-61. PubMed ID: 10155601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.
    Parrón I; Planas C; Godoy P; Manzanares-Laya S; Martínez A; Sala MR; Minguell S; Torner N; Jané M; Domínguez A;
    Hum Vaccin Immunother; 2017 Feb; 13(2):423-427. PubMed ID: 27925847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis A vaccines.
    Nothdurft HD
    Expert Rev Vaccines; 2008 Jul; 7(5):535-45. PubMed ID: 18564009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries.
    Pedersini R; Marano C; De Moerlooze L; Chen L; Vietri J
    Travel Med Infect Dis; 2016; 14(3):221-32. PubMed ID: 27000975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should British soldiers be vaccinated against hepatitis A? An economic analysis.
    Jefferson TO; Behrens RH; Demicheli V
    Vaccine; 1994 Nov; 12(15):1379-83. PubMed ID: 7887014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for Prevention of Hepatitis A Based on a Cost-Effectiveness Analysis.
    Tormans G; Van Damme P ; Van Doorslaer E
    J Travel Med; 1994 Sep; 1(3):127-135. PubMed ID: 9815326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.